412 related articles for article (PubMed ID: 12673648)
1. Genetic testing for a BRCA1 mutation: prophylactic surgery and screening behavior in women 2 years post testing.
Botkin JR; Smith KR; Croyle RT; Baty BJ; Wylie JE; Dutson D; Chan A; Hamann HA; Lerman C; McDonald J; Venne V; Ward JH; Lyon E
Am J Med Genet A; 2003 Apr; 118A(3):201-9. PubMed ID: 12673648
[TBL] [Abstract][Full Text] [Related]
2. Prophylactic surgery decisions and surveillance practices one year following BRCA1/2 testing.
Lerman C; Hughes C; Croyle RT; Main D; Durham C; Snyder C; Bonney A; Lynch JF; Narod SA; Lynch HT
Prev Med; 2000 Jul; 31(1):75-80. PubMed ID: 10896846
[TBL] [Abstract][Full Text] [Related]
3. Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation.
Meijers-Heijboer EJ; Verhoog LC; Brekelmans CT; Seynaeve C; Tilanus-Linthorst MM; Wagner A; Dukel L; Devilee P; van den Ouweland AM; van Geel AN; Klijn JG
Lancet; 2000 Jun; 355(9220):2015-20. PubMed ID: 10885351
[TBL] [Abstract][Full Text] [Related]
4. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B
Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443
[TBL] [Abstract][Full Text] [Related]
5. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium.
Burke W; Daly M; Garber J; Botkin J; Kahn MJ; Lynch P; McTiernan A; Offit K; Perlman J; Petersen G; Thomson E; Varricchio C
JAMA; 1997 Mar; 277(12):997-1003. PubMed ID: 9091675
[TBL] [Abstract][Full Text] [Related]
6. Bilateral prophylactic oophorectomy and ovarian cancer screening following BRCA1/BRCA2 mutation testing.
Schwartz MD; Kaufman E; Peshkin BN; Isaacs C; Hughes C; DeMarco T; Finch C; Lerman C
J Clin Oncol; 2003 Nov; 21(21):4034-41. PubMed ID: 14581427
[TBL] [Abstract][Full Text] [Related]
7. Long-term outcomes of BRCA1/BRCA2 testing: risk reduction and surveillance.
Schwartz MD; Isaacs C; Graves KD; Poggi E; Peshkin BN; Gell C; Finch C; Kelly S; Taylor KL; Perley L
Cancer; 2012 Jan; 118(2):510-7. PubMed ID: 21717445
[TBL] [Abstract][Full Text] [Related]
8. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
[TBL] [Abstract][Full Text] [Related]
9. Bilateral prophylactic mastectomy in BRCA mutation carriers: what surgeons need to know.
Franceschini G; Di Leone A; Terribile D; Sanchez MA; Masetti R
Ann Ital Chir; 2019; 90():1-2. PubMed ID: 30872561
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation.
Anderson K; Jacobson JS; Heitjan DF; Zivin JG; Hershman D; Neugut AI; Grann VR
Ann Intern Med; 2006 Mar; 144(6):397-406. PubMed ID: 16549852
[TBL] [Abstract][Full Text] [Related]
11. One year follow-up of women opting for presymptomatic testing for BRCA1 and BRCA2: emotional impact of the test outcome and decisions on risk management (surveillance or prophylactic surgery).
Lodder LN; Frets PG; Trijsburg RW; Meijers-Heijboer EJ; Klijn JG; Seynaeve C; van Geel AN; Tilanus MM; Bartels CC; Verhoog LC; Brekelmans CT; Burger CW; Niermeijer MF
Breast Cancer Res Treat; 2002 May; 73(2):97-112. PubMed ID: 12088120
[TBL] [Abstract][Full Text] [Related]
12. Surveillance behavior and prophylactic surgery after predictive testing for hereditary breast/ovarian cancer.
Claes E; Evers-Kiebooms G; Decruyenaere M; Denayer L; Boogaerts A; Philippe K; Legius E
Behav Med; 2005; 31(3):93-105. PubMed ID: 16252621
[TBL] [Abstract][Full Text] [Related]
13. Cancer prevention and screening practices among women at risk for hereditary breast and ovarian cancer after genetic counseling in the community setting.
Morgan D; Sylvester H; Lucas FL; Miesfeldt S
Fam Cancer; 2009; 8(4):277-87. PubMed ID: 19347608
[TBL] [Abstract][Full Text] [Related]
14. Impact of Genetic Testing on Risk-Management Behavior of Black Breast Cancer Survivors: A Longitudinal, Observational Study.
Conley CC; Kasting ML; Augusto BM; Garcia JD; Cragun D; Gonzalez BD; Kim J; Ashing KT; Knott CL; Hughes-Halbert C; Pal T; Vadaparampil ST
Ann Surg Oncol; 2020 May; 27(5):1659-1670. PubMed ID: 31677107
[TBL] [Abstract][Full Text] [Related]
15. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers.
Rebbeck TR; Levin AM; Eisen A; Snyder C; Watson P; Cannon-Albright L; Isaacs C; Olopade O; Garber JE; Godwin AK; Daly MB; Narod SA; Neuhausen SL; Lynch HT; Weber BL
J Natl Cancer Inst; 1999 Sep; 91(17):1475-9. PubMed ID: 10469748
[TBL] [Abstract][Full Text] [Related]
16. Utilization of breast cancer screening in a clinically based sample of women after BRCA1/2 testing.
Peshkin BN; Schwartz MD; Isaacs C; Hughes C; Main D; Lerman C
Cancer Epidemiol Biomarkers Prev; 2002 Oct; 11(10 Pt 1):1115-8. PubMed ID: 12376518
[TBL] [Abstract][Full Text] [Related]
17. A simulation model to predict the impact of prophylactic surgery and screening on the life expectancy of BRCA1 and BRCA2 mutation carriers.
Sigal BM; Munoz DF; Kurian AW; Plevritis SK
Cancer Epidemiol Biomarkers Prev; 2012 Jul; 21(7):1066-77. PubMed ID: 22556274
[TBL] [Abstract][Full Text] [Related]
18. Decision analysis of prophylactic surgery or screening for BRCA1 mutation carriers: a more prominent role for oophorectomy.
van Roosmalen MS; Verhoef LC; Stalmeier PF; Hoogerbrugge N; van Daal WA
J Clin Oncol; 2002 Apr; 20(8):2092-100. PubMed ID: 11956270
[TBL] [Abstract][Full Text] [Related]
19. Online tool to guide decisions for BRCA1/2 mutation carriers.
Kurian AW; Munoz DF; Rust P; Schackmann EA; Smith M; Clarke L; Mills MA; Plevritis SK
J Clin Oncol; 2012 Feb; 30(5):497-506. PubMed ID: 22231042
[TBL] [Abstract][Full Text] [Related]
20. Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation.
Meijers-Heijboer H; Brekelmans CT; Menke-Pluymers M; Seynaeve C; Baalbergen A; Burger C; Crepin E; van den Ouweland AW; van Geel B; Klijn JG
J Clin Oncol; 2003 May; 21(9):1675-81. PubMed ID: 12721241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
